Novo Nordisk A/S Reports Positive Results From First Phase 3 Trial With Long-Acting Factor IX for Treatment of Hemophilia B

BAGSVAERD, DENMARK--(Marketwired - May 17, 2013) - Novo Nordisk today announced the completion of paradigm™ 2, the first phase 3 trial with a long-acting FIX derivative, N9-GP (glycopegylated recombinant factor IX), for haemophilia B patients. Paradigm™ 2 is a multi-centre, blinded trial evaluating the safety and efficacy of N9-GP when used for on-demand or prophylactic treatment in patients with haemophilia B.

Company announcement No 37 / 2013: http://hugin.info/2013/R/1702902/562797.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE

[HUG#1702902]